STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
L
Not yet recruiting
- Lymphoma, Non-Hodgkin Lymphoma, B-Cell
- BAFF CAR-T
- (no location specified)
2022-04-01
Apr 1, 2022C
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +3 more
- (no location specified)
2021-07-20
Jul 20, 2021V
Not yet recruiting
- Non-hodgkin Lymphoma,B Cell
- Vaccination Failure
- Immunological analyses
- (no location specified)
2021-09-13
Sep 13, 2021M
Recruiting
- Lymphoma, Non-Hodgkin
- +4 more
- Rochester, MinnesotaMayo Clinic
2021-08-30
Aug 30, 2021U
Active, not recruiting
- Non Hodgkin Lymphoma
- Cologne, Germany
- +1 more
2022-03-02
Mar 2, 2022S
Recruiting
- Lymphoma, Non-Hodgkin
- Lymphoma, Hodgkin
- Seoul, Korea, Republic ofSamsung Medical Center
2021-03-21
Mar 21, 2021U
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
- Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
2021-12-03
Dec 3, 2021C
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
- Scottsdale, Arizona
- +5 more
2022-04-05
Apr 5, 2022M
Terminated
- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular, Marginal Zone
- Nagoya-shi, Aichi, Japan
- +3 more
2021-08-17
Aug 17, 2021D
Completed
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Imprime PGG
- Rituximab
- Boston, MassachusettsDana Farber Cancer Institute
2022-03-15
Mar 15, 2022A
Not yet recruiting
- Lymphoma, Non-Hodgkin
- Lymphoma, Hodgkin
- intervention
- (no location specified)
2022-02-09
Feb 9, 2022U
Active, not recruiting
- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Transformed B-cell Non-Hodgkin Lymphoma
- Ibrutinib
- Laboratory Biomarker Analysis
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-01-20
Jan 20, 2022B
Recruiting
- Diffuse Large B-Cell Lymphoma
- +14 more
- La Jolla, California
- +1 more
2022-01-10
Jan 10, 2022W
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Stem cell infusion
- +5 more
- Saint Louis, MissouriWashington University
2022-01-12
Jan 12, 2022C
Terminated
- Hodgkin Disease
- Lymphoma, Non-hodgkin
- New York, New YorkColumbia University Irving Medical Center - Center for Lymphoid
2021-06-28
Jun 28, 2021N
Completed
- Leukemia
- +3 more
- Bethesda, MarylandNational Cancer Institute (NCI), 9000 Rockville Pike
2022-04-07
Apr 7, 2022U
Recruiting
- Follicular Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- Pembrolizumab
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-12-15
Dec 15, 2021H
Recruiting
- Lymphoma, Non-Hodgkin
- RO7443904
- +3 more
- Melbourne, Victoria, Australia
- +1 more
2022-03-21
Mar 21, 2022S
Active, not recruiting
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
- Seoul, Korea, Republic ofSeoul National University Hospital
2022-02-04
Feb 4, 2022S
Recruiting
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- +4 more
- Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
- R-CHOP; R-DA-EPOCH; R-HD MTX
- Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital
2021-12-07
Dec 7, 2021N
Withdrawn
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Tisagenlecleucel
- (no location specified)
2022-02-25
Feb 25, 2022T
Completed
- Hodgkin Lymphoma, Adult
- Non-Hodgkin Lymphoma, Adult
- SPECT with 99mTc-1-thio-D-glucose
- Tomsk, Russian FederationTomskNRMC
2021-03-30
Mar 30, 2021A
Not yet recruiting
- Non Hodgkin Lymphoma
- (no location specified)
2022-03-31
Mar 31, 2022H
Recruiting
- Non-hodgkin's Lymphoma
- CD19+22 CAR-T cells
- Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
2022-01-11
Jan 11, 2022M
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
- Rochester, MinnesotaMayo Clinic
2022-03-25
Mar 25, 2022